Claims
- 1. A wound management product comprising a substrate carrying a cationic compound capable of binding microbes located on the surface of a wound, said cationic compound having an effective charge density of from about 0.1 microequivalents/g to about 8000 microequivalents/g and a positive charge imparting a Positive Charge Index of at least about 52 to said product.
- 2. The product as set forth in claim 1 wherein the cationic compound is selected from the group consisting of Bufloc 535, Nalco 7607, Reten 201, Cypro 515, Bufloc 5554, Busperse 5030, cationic polymers, inorganic cationic species, biological cationic polymers, modified chitosan, octadecyldimethyltrimethoxylsilpropylammonium chloride, octadecyldimethoxylsilpropylammonium chloride, polyacrylamides, diallydimethylammonium chloride, dicyandiamideformaldehyde, epichlorohydrinamine, cationic liposomes, modified starch, l-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, l-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate, trimethylsilylmodimethicone, amodimethicone, polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquaternium-7, polyquaternium-8, polyquaternium-9, polyquaternium-10, polyquaternium-ll, polyquaternium-12, polyquaternium-13, polyquaternium-14, polyquaternium-15, polyquaternium-16, polyquaternium-17, polyquaternium-18, polyquaternium-19, polyquaternium-20, polyquaternium-22, polyquaternium-24, polyquaternium-27, polyquaternium-28, polyquaternium-29, polyquaternium-30, polyquaternium-32, polyquaternium-33, polyquaternium-34, polyquaternium-35, polyquaternium-36, polyquaternium-37, polyquaternium-39, polysilicone-1, polysilicone-2, and mixtures and combinations thereof.
- 3. The product as set forth in claim 1 wherein the cationic compound is selected from the group consisting of quaternary compounds, polyelectrolytes, octadecyldimethoxylsilpropylammonium chloride, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, and 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate.
- 4. The product as set forth in claim 1 wherein the substrate is selected from the group consisting of coform materials, woven webs, non-woven webs, spunbonded fabrics, meltblown fabrics, wet-laid fabrics, needle punched webs, cellulosic material, and mixtures and combinations thereof.
- 5. The product as set forth in claim 4 wherein the product is selected from the group consisting of wraps, wipes, gauzes, gauze wraps, bandages, and dressings.
- 6. The product as set forth in claim 1 wherein the substrate comprises from about 0.1% (by weight of the substrate) to about 25% (by weight of the substrate) of the cationic compound.
- 7. The product as set forth in claim 1 wherein the substrate comprises from about 0.1% (by weight of the substrate) to about 10% (by weight of the substrate) of the cationic compound.
- 8. The product as set forth in claim 1 wherein the product has a Positive Charge Index of at least about 55.
- 9. The product as set forth in claim 1 wherein the product has a Positive Charge Index of at least about 60.
- 10. The product as set forth in claim 1 wherein the Positive Charge Index of the product is determined by utilizing an anionic dye binding assay.
- 11. The product as set forth in claim 1 wherein the Positive Charge Index of the product is determined by utilizing an anionic dye binding assay selected from the group consisting of an Eosin Y anionic dye binding assay and an Eosin B anionic dye binding assay.
- 12. The product as set forth in claim 1 wherein the Positive Charge Index of the product is determined by utilizing an Eosin Y anionic dye binding assay.
- 13. A wound management product comprising a substrate carrying a cationic compound capable of binding microbes located on the surface of a wound, said cationic compound having an effective charge density of from about 500 microequivalents/g to about 8000 microequivalents/g and a positive charge imparting a Positive Charge Index of at least about 52 to said product.
- 14. The product as set forth in claim 13 wherein the cationic compound is selected from the group consisting of Bufloc 535, Nalco 7607, Reten 201, Cypro 515, Bufloc 5554, Busperse 5030, cationic polymers, inorganic cationic species, biological cationic polymers, modified chitosan, octadecyldimethyltrimethoxylsilpropylammonium chloride, octadecyldimethoxylsilpropylammonium chloride, polyacrylamides, diallydimethylammonium chloride, dicyandiamideformaldehyde, epichlorohydrinamine, cationic liposomes, modified starch, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate, trimethylsilylmodimethicone, amodimethicone, polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquaternium-7, polyquaternium-8, polyquaternium-9, polyquaternium-10, polyquaternium-11, polyquaternium-12, polyquaternium-13, polyquaternium-14, polyquaternium-15, polyquaternium-16, polyquaternium-17, polyquaternium-18, polyquaternium-19, polyquaternium-20, polyquaternium-22, polyquaternium-24, polyquaternium-27, polyquaternium-28, polyquaternium-29, polyquaternium-30, polyquaternium-32, polyquaternium-33, polyquaternium-34, polyquaternium-35, polyquaternium-36, polyquaternium-37, polyquaternium-39, polysilicone-1, polysilicone-2, and mixtures and combinations thereof.
- 15. The product as set forth in claim 13 wherein the cationic compound is selected from the group consisting of quaternary compounds, polyelectrolytes, octadecyldimethoxylsilpropylammonium chloride, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, and 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate.
- 16. The product as set forth in claim 13 wherein the substrate is selected from the group consisting of coform materials, woven webs, non-woven webs, spunbonded fabrics, meltblown fabrics, wet-laid fabrics, needle punched webs, cellulosic material, and mixtures and combinations thereof.
- 17. The product as set forth in claim 16 wherein the product is selected from the group consisting of wraps, wipes, gauzes, gauze wraps, bandages, and dressings.
- 18. The product as set forth in claim 13 wherein the substrate comprises from about 0.1% (by weight of the substrate) to about 25% (by weight of the substrate) of the cationic compound.
- 19. The product as set forth in claim 13 wherein the substrate comprises from about 0.1% (by weight of the substrate) to about 10% (by weight of the substrate) of the cationic compound.
- 20. The product as set forth in claim 13 wherein the product has a Positive Charge Index of at least about 55.
- 21. The product as set forth in claim 13 wherein the product has a Positive Charge Index of at least about 60.
- 22. The product as set forth in claim 13 wherein the Positive Charge Index of the product is determined by utilizing an anionic dye binding assay.
- 23. The product as set forth in claim 13 wherein the Positive Charge Index of the product is determined by utilizing an anionic dye binding assay selected from the group consisting of an Eosin Y anionic dye binding assay and an Eosin B anionic dye binding assay.
- 24. The product as set forth in claim 13 wherein the Positive Charge Index of the product is determined by utilizing an Eosin Y anionic dye binding assay.
- 25. A wound management product comprising a substrate carrying a cationic compound capable of binding microbes located on the surface of a wound, said cationic compound having an effective charge density of from about 1000 microequivalents/9 to about 8000 microequivalents/g and a positive charge imparting a Positive Charge Index of at least about 52 to said product.
- 26. The product as set forth in claim 25 wherein the cationic compound is selected from the group consisting of Bufloc 535, Nalco 7607, Reten 201, Cypro 515, Bufloc 5554, Busperse 5030, cationic polymers, inorganic cationic species, biological cationic polymers, modified chitosan, octadecyldimethyltrimethoxylsilpropylammonium chloride, octadecyldimethoxylsilpropylammonium chloride, polyacrylamides, diallydimethylammonium chloride, dicyandiamideformaldehyde, epichlorohydrinamine, cationic liposomes, modified starch, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate, trimethylsilylmodimethicone, amodimethicone, polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquaternium-7, polyquaternium-8, polyquaternium-9, polyquaternium-10, polyquaternium-11, polyquaternium-12, polyquaternium-13, polyquaternium-14, polyquaternium-15, polyquaternium-16, polyquaternium-17, polyquaternium-18, polyquaternium-19, polyquaternium-20, polyquaternium-22, polyquaternium-24, polyquaternium-27, polyquaternium-28, polyquaternium-29, polyquaternium-30, polyquaternium-32, polyquaternium-33, polyquaternium-34, polyquaternium-35, polyquaternium-36, polyquaternium-37, polyquaternium-39, polysilicone-1, polysilicone-2, and mixtures and combinations thereof.
- 27. The product as set forth in claim 25 wherein the cationic compound is selected from the group consisting of quaternary compounds, polyelectrolytes, octadecyldimethoxylsilpropylammonium chloride, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, and 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate.
- 28. The product as set forth in claim 25 wherein the substrate is selected from the group consisting of coform materials, woven webs, non-woven webs, spunbonded fabrics, meltblown fabrics, wet-laid fabrics, needle punched webs, cellulosic material, and mixtures and combinations thereof.
- 29. The product as set forth in claim 27 wherein the product is selected from the group consisting of wraps, wipes, gauzes, gauze wraps, bandages, and dressings.
- 30. The product as set forth in claim 25 wherein the substrate comprises from about 0.1% (by weight of the substrate) to about 25% (by weight of the substrate) of the cationic compound.
- 31. The product as set forth in claim 25 wherein the substrate comprises from about 0.1% (by weight of the substrate) to about 10% (by weight of the substrate) of the cationic compound.
- 32. The product as set forth in claim 25 wherein the product has a Positive Charge Index of at least about 55.
- 33. The product as set forth in claim 25 wherein the product has a Positive Charge Index of at least about 60.
- 34. The product as set forth in claim 25 wherein the Positive Charge Index of the product is determined by utilizing an anionic dye binding assay.
- 35. The product as set forth in claim 25 wherein the Positive Charge Index of the product is determined by utilizing an anionic dye binding assay selected from the group consisting of an Eosin Y anionic dye binding assay and an Eosin B anionic dye binding assay.
- 36. The product as set forth in claim 25 wherein the Positive Charge Index of the product is determined by utilizing an Eosin Y anionic dye binding assay.
- 37. A wound management product comprising a woven web material carrying a cationic compound capable of binding microbes located on the surface of a wound, said cationic compound having an effective charge density of from about 0.1 microequivalents/g to about 8000 microequivalents/g and a positive charge imparting a Positive Charge Index of at least about 52 to said product.
- 38. The product as set forth in claim 37 wherein the product has a Positive Charge Index of at least about 60.
- 39. The product as set forth in claim 37 wherein the cationic compound is selected from the group consisting of Bufloc 535, Nalco 7607, Reten 201, Cypro 515, Bufloc 5554, Busperse 5030, cationic polymers, inorganic cationic species, biological cationic polymers, modified chitosan, octadecyldimethyltrimethoxylsilpropylammonium chloride, octadecyldimethoxylsilpropylammonium chloride, polyacrylamides, diallydimethylammonium chloride, dicyandiamideformaldehyde, epichlorohydrinamine, cationic liposomes, modified starch, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate, trimethylsilylmodimethicone, amodimethicone, polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquaternium-7, polyquaternium-8, polyquaternium-9, polyquaternium-10, polyquaternium-11, polyquaternium-12, polyquaternium-13, polyquaternium-14, polyquaternium-15, polyquaternium-16, polyquaternium-17, polyquaternium-18, polyquaternium-19, polyquaternium-20, polyquaternium-22, polyquaternium-24, polyquaternium-27, polyquaternium-28, polyquaternium-29, polyquaternium-30, polyquaternium-32, polyquaternium-33, polyquaternium-34, polyquaternium-35, polyquaternium-36, polyquaternium-37, polyquaternium-39, polysilicone-1, polysilicone-2, and mixtures and combinations thereof.
- 40. The product as set forth in claim 37 wherein the cationic compound is selected from the group consisting of quaternary compounds, polyelectrolytes, octadecyldimethoxylsilpropylammonium chloride, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, and 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate.
- 41. A wound management product comprising a non-woven web material carrying a cationic compound capable of binding microbes located on the surface of a wound, said cationic compound having an effective charge density of from about 0.1 microequivalents/g to about 8000 microequivalents/g and a positive charge imparting a Positive Charge Index of at least about 52 to said product.
- 42. The product as set forth in claim 41 wherein the product has a Positive Charge Index of at least about 60.
- 43. The product as set forth in claim 41 wherein the cationic compound is selected from the group consisting of Bufloc 535, Nalco 7607, Reten 201, Cypro 515, Bufloc 5554, Busperse 5030, cationic polymers, inorganic cationic species, biological cationic polymers, modified chitosan, octadecyldimethyltrimethoxylsilpropylammonium chloride, octadecyldimethoxylsilpropylammonium chloride, polyacrylamides, diallydimethylammonium chloride, dicyandiamideformaldehyde, epichlorohydrinamine, cationic liposomes, modified starch, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate, trimethylsilylmodimethicone, amodimethicone, polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquaternium-7, polyquaternium-8, polyquaternium-9, polyquaternium-10, polyquaternium-11, polyquaternium-12, polyquaternium-13, polyquaternium-14, polyquaternium-15, polyquaternium-16, polyquaternium-17, polyquaternium-18, polyquaternium-19, polyquaternium-20, polyquaternium-22, polyquaternium-24, polyquaternium-27, polyquaternium-28, polyquaternium-29, polyquaternium-30, polyquaternium-32, polyquaternium-33, polyquaternium-34, polyquaternium-35, polyquaternium-36, polyquaternium-37, polyquaternium-39, polysilicone-1, polysilicone-2, and mixtures and combinations thereof.
- 44. The product as set forth in claim 41 wherein the cationic compound is selected from the group consisting of quaternary compounds, polyelectrolytes, octadecyldimethoxylsilpropylammonium chloride, 1-methyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline methylsulfate, and 1-ethyl-2-Noroleyl-3-oleyl-amidoethyl imidazoline ethylsulfate.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Patent Application No. 60/394,634 filed on Jul. 9, 2002, the entirety of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60394634 |
Jul 2002 |
US |